Table 3.

Vaccination status of study participants after 2 years.

Vaccination coverage	N=80
Yes, n (%)	74/80 (92.5%)
1° Dose, n (%)	74/80 (92.5%)
Coronavac/(Sinovac)	17/80 (21.3%)
Pfizer/(BioNTech)	11/80 (13.8%)
Astrazeneca/(Oxford)	44/80 (55.0%)
Janssen	2/80 (2.5%)
2° Dose, n (%)	72/80 (90%)
Coronavac/(Sinovac)	17/80 (21.3%)
Pfizer/(BioNTech)	12/80 (15.0%)
Astrazeneca/(Oxford)	43/80 (53.8%)
3° Dose, n (%)	54/80 (67.5%)
Coronavac/(Sinovac)	44/80 (55.0%)
Pfizer/(BioNTech)	10/80 (12.5%)
4° Dose, n (%)	31/80 (38.8%)
Coronavac/(Sinovac)	1/80 (1.3%)
Pfizer/(BioNTech)	22/80 (27.5%)
Astrazeneca/(Oxford)	8/80 (10.0%)